Past and present: a bibliometric study on the treatment of recurrent ovarian cancer

Author:

Hao Xiao-yuan1,Li Miao-ling1,Song Wen-wei1,Guo Yi1

Affiliation:

1. the Second Affiliated Hospital of Xuzhou Medical University

Abstract

Abstract Background Ovarian cancer (OC) is a gynecological malignancy with high mortality worldwide. The poor prognosis of OC is usually attributed to its recurrence-prone signature. Recently, mortality from OC has exhibited a downward trend. These favorable patterns likely find their main driving factor in advancements in novel therapeutic regimens. However, visualized analysis of the application of these new drugs on women with recurrent OC (ROC) is lacking. Therefore, we aimed to summarize changing paradigms in the ROC treatment using the bibliometric method. Methods Documents on ROC treatment were systematically collected from the MEDLINE database and Web of Science Core Collection (WOSCC). The retrieved documents were exported in the plain text file format, and files were named and saved to the paths specified by the Java application. Microsoft Excel (version 2010), Citespace (6.2.R4) and VOSviewer (1.6.19) were used for data analysis and included the following: (1) annual publication trend; (2) contributions of countries, institutions and authors; (3) co-citation of journals and references; and (4) co-occurrence of keywords. Results A total of 914 documents published in the MEDLINE and 9,980 ones in WOSCC were retrieved. There has been an upward trend in the productivity of publications on ROC treatment on by years. The United States was the leading contributor in this field, and the University of Texas System was the most productive institution. Giovanni Scambia and Maurie Markman were the research leaders for ROC treatment. Gynecologic Oncology was the journal with most citation frequency. The reference entitled with “Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer” got highest centrality of 0.14 in the co-citation network. Keyword analysis indicated that current treatment of ROC mainly focused on the platinum-based anticancer drugs, paclitaxel, angiogenesis inhibitors (AIs) and poly (ADP-ribose) polymerase inhibitors (PARPis). Conclusion Scholars from all over the world have taken active part in the development of ROC treatment. International top journals and professional periodicals on gynecologic oncology have been the main sources of the hotspots and frontiers in this field. Maintenance treatment based on AIs or (and) PARPis has become an important adjunct to chemotherapy based on platinum agents and paclitaxel for ROC patients.

Publisher

Research Square Platform LLC

Reference31 articles.

1. [Cancer statistics in China, 2016];Zheng RS;Zhonghua zhong liu za zhi [Chinese journal of oncology],2023

2. Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics. 2023. CA: a cancer journal for clinicians. 2023;73(1):17–48.

3. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review;Richardson DL;JAMA Oncol,2023

4. European cancer mortality predictions for the year 2022 with focus on ovarian cancer;Dalmartello M;Ann Oncol,2022

5. European trends in ovarian cancer mortality, 1990–2020 and predictions to 2025;Wojtyla C;Eur J cancer (Oxford England: 1990),2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3